Dilaforette is a drug development company developing a heparan sulphate mimetic, sevuparin, a proprietary polysaccharide drug derived from heparin. Sevuparin is intended to be used as an anti-adhesive therapy and has therefore been designed to retain the anti-adhesives effects of heparin, while reducing the anti-coagulant properties. Sevuparin, with its strong anti-adhesive effects, has the potential to be of clinical use in several therapeutic conditions. Dilaforette is currently developing sevuparin for severe malaria as well as sickle cell disease.
Dilaforette, a Swedish drug development company, founded by leading scientists in malaria from Karolinska Institute as well as leading experts in the field of heparin and drug development from Uppsala University and the Swedish pharmaceutical industry together with Karolinska Innovation AB.